MuriGen

About

MuriGen Therapeutics, a Melbourne spinout of the Walter and Eliza Hall Institute, develops therapeutics for arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia via a proprietary drug-discovery platform and Zenyth collaborations.

Mission

MuriGen Therapeutics, spun out from the Walter and Eliza Hall Institute of Medical Research and based in Melbourne, develops a portfolio of novel drugs for unmet needs across arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia. Its flagship program is a new class of drugs targeting arthritis and other inflammatory diseases, undertaken in collaboration with Zenyth Therapeutics. The company’s proprietary drug discovery platform underpins multiple collaborative initiatives focused on novel drug targets for blood conditions and inflammatory diseases. The platform was further validated by a recent discovery of the mechanism controlling survival of certain blood cells. Management says the capital will be used to progress two lead drug development programs in inflammation and thrombocytopenia and to pursue new opportunities. The article does not report revenue or user metrics.

Quick Facts